Gene therapy isn't new. Scientists have been trying to fix broken genes since the 1990s. What's new is that it finally works reliably. The early viral-vector approaches were clumsy -- they delivered therapeutic genes randomly into the genome, sometimes causing cancer. CRISPR changed everything by allowing precise edits at specific locations in your DNA.
In 2023, the FDA approved Casgevy -- the first CRISPR-based gene therapy -- for sickle cell disease. One treatment. One edit. A lifetime cure for a disease that has tortured millions. The cost was $2.2 million. That sounds insane until you compare it to a lifetime of transfusions, hospitalizations, and pain management that runs $3-6 million per patient.
The door isn't just open. It's been kicked off its hinges.
CRISPR's biggest weakness is that it cuts the DNA double strand to make its edit. That works, but it creates opportunities for errors -- insertions, deletions, rearrangements. For a disease like sickle cell where you're editing blood stem cells outside the body and checking your work, that's manageable. For editing genes inside a living human? Too risky.
Base editing and prime editing solve this. Developed by David Liu's lab at Harvard, these techniques can change individual DNA letters -- A to G, C to T -- without ever cutting the strand. Prime editing can even insert or delete small sequences with precision that CRISPR can't match.
This matters for longevity because the genetic variants that influence how fast you age aren't single broken genes. They're subtle differences -- a letter here, a sequence there -- that nudge your biology toward faster or slower aging. Fixing them requires a scalpel, not a machete.
Researchers have identified several genes strongly associated with exceptional longevity. FOXO3 -- people with certain variants of this gene are 2.7 times more likely to live past 100. Klotho -- a gene whose protein product protects against kidney disease, cognitive decline, and cardiovascular aging. TERT -- the gene encoding telomerase, the enzyme that rebuilds the protective caps on your chromosomes.
In animal models, upregulating these genes extends lifespan by 20-40%. Gene therapies that deliver extra copies of TERT or klotho via adeno-associated virus (AAV) vectors have shown promising results in mice, with human trials in early planning stages.
We're not editing humans for longevity yet. But the tools exist, the targets are identified, and the regulatory pathway has been established. The question is when, not if.
Gene therapy for longevity raises questions that we haven't had to answer before. If you can edit your genes to age slower, who gets access? If germline editing becomes possible, should parents be allowed to give their children longevity genes? What happens to societies where some people age normally and others don't?
These aren't hypothetical anymore. They're engineering problems with ethical constraints, and the technology is moving faster than the ethics committees can convene. The first approved longevity gene therapy will likely arrive before we've agreed on the rules governing it.
Gene therapy started as a way to fix diseases. It's becoming a way to fix aging itself. And whether that terrifies you or excites you probably depends on how much time you think you have left.
Science-backed health tips delivered every week.